Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

BACKGROUND: The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown. METHODS: We retrospectively analyzed data from breast cancer patients who began treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fan, Huang, Xiang, Sun, Chunxiao, Li, Jianbin, Wang, Biyun, Yan, Min, Jin, Feng, Wang, Haibo, Zhang, Jin, Fu, Peifen, Zeng, Tianyu, Wang, Jian, Li, Wei, Li, Yongfei, Yang, Mengzhu, Li, Jun, Wu, Hao, Fu, Ziyi, Yin, Yongmei, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104485/
https://www.ncbi.nlm.nih.gov/pubmed/32223744
http://dx.doi.org/10.1186/s12885-020-6639-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104485/
https://www.ncbi.nlm.nih.gov/pubmed/32223744
http://dx.doi.org/10.1186/s12885-020-6639-4

Ejemplares similares